The PREDICATE research aims to study the effect of chemotherapy on myocardial function and structure, presenting groups of BC patients for whom GLS assessment and a proposed panel of biomarkers (cTnI, BNP, D-dimer, CRP, MPO, and Gal-3) would be the most appropriate for the timely diagnosis and treatment of cardiotoxicity. The gene discussed is TNNI3; the disease is breast cancer.